(19)
(11) EP 4 448 763 A1

(12)

(43) Date of publication:
23.10.2024 Bulletin 2024/43

(21) Application number: 22840080.0

(22) Date of filing: 16.12.2022
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/1137; C12Y 302/01045; C12N 2310/14
(86) International application number:
PCT/EP2022/086504
(87) International publication number:
WO 2023/111336 (22.06.2023 Gazette 2023/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 17.12.2021 EP 21215509

(71) Applicants:
  • F. Hoffmann-La Roche AG
    4070 Basel (CH)
  • Genentech, Inc.
    South San Francisco, CA 94080-4990 (US)

(72) Inventors:
  • BRAUN, Johannes
    2970 Hørsolm (DK)
  • CORDINER, Ross
    2970 Hørsolm (DK)
  • KIELPINSKI, Lukasz
    2970 Hørsolm (DK)
  • BINGOL, Baris
    South San Francisco, CA 94080-4990 (US)

(74) Representative: Berendt, Frank Joachim Nathanael et al
F. Hoffmann-La Roche AG Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)

   


(54) OLIGONUCLEOTIDE GBA AGONISTS